<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8344">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998320</url>
  </required_header>
  <id_info>
    <org_study_id>GEFR1044015</org_study_id>
    <nct_id>NCT02998320</nct_id>
  </id_info>
  <brief_title>Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis</brief_title>
  <official_title>Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study measures the proportion of enrolled patients taking the uninterrupted HIV
      post-exposure prophylaxis Genvoya for four weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study measures the proportion of enrolled patients taking the uninterrupted HIV
      post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for
      four Weeks.

      Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a
      selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A
      subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and
      nucleoside analogue àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse
      transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine
      monophosphate analogue).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients taking the uninterrupted HIV post-exposure prophylaxis for four weeks</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Risk</condition>
  <arm_group>
    <arm_group_label>Genvoya</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genvoya</intervention_name>
    <description>Oral use (one tablet each day); 150/150/200/10 mg; 28 days</description>
    <arm_group_label>Genvoya</arm_group_label>
    <other_name>(E/C/F/TAF) ATC Code: J05AR18</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  an age above 18 years

          -  consultation within 48 hours following a risk of HIV transmission (blood or sexual
             contact)

          -  indication for HIV post-exposure prophylaxis (according to French guidelines)

          -  person able to understand the nature of the study

          -  person who signed his consent form to participate in the study

        Exclusion Criteria:

          -  person exposed to HIV risk from person infected by HIV, whose therapeutic history
             justifies the prescription of another combination of antiretroviral drugs

          -  contraindications to the prescription of Genvoy

          -  other medical contraindications

          -  person infected by hepatitis B virus

          -  pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerard Pellissier</last_name>
    <phone>+33 1 57 27 78 71</phone>
    <email>gerard.pellissier@geres.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Rey</last_name>
    <phone>+33 3 69 55 05 01</phone>
    <email>david.rey@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 19, 2016</lastchanged_date>
  <firstreceived_date>December 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
